Researchers including Stephan, Cummings and Fitzgerald introduced a novel oral foam formulation intended to deliver gene therapy to constrictive esophageal carcinomas, aiming to overcome access limitations for tumors in the upper digestive tract. The approach packages therapeutic nucleic acids into a foam that adheres to the esophageal mucosa after swallowing, enabling localized transduction without invasive endoscopic procedures. The proof‑of‑concept study demonstrates that a swallowed foam can retain contact with target tissue long enough for gene transfer in preclinical models, addressing delivery challenges that limit gene therapy for esophageal and other luminal cancers. Oral foam delivery is a niche but potentially scalable route for localized therapies when systemic exposure or surgical access is problematic.